European Journal of Nuclear Medicine and Molecular Imaging

Dynamic positron emission tomography (PET) with long axial field-of-view (LAFOV) scanners enables multi-organ imaging and kinetic quantification beyond static (late-phase) imaging; however, the long times typically required for dynamic acquisitions remain clinically impractical. This study evaluates a deep learning (DL) framework to enable abbreviated dynamic PET acquisitions, comparing single-time-window (STW, early dynamic data only) and dual-time-window (DTW, early dynamic data plus a late 5-min static frame) protocols with early dynamic scan durations of 5-30 min and dose levels ranging from 360 MBq to 18 MBq. Seventeen 60-min dynamic [18F]FDG datasets were first motion-corrected using a staggered FALCON pipeline and then used to train and test a spatiotemporal DL model for autoregressive frame prediction. Performance was assessed across the full quantitative workflow, from DL-predicted frames and time-activity curves to organ-based kinetic modeling and voxel-wise parametric imaging in multiple tissues and two patient cohorts. DTW protocols consistently outperformed STW, better preserving late-phase kinetics. For a 15-min early dynamic scan, adding a late 5-min scan reduced mean absolute Ki difference from 23% (STW) to 17% (DTW) in the liver and from 26% to 15% in the thalamus. DTW + DL further reduced errors to [≤]10% in the liver, thalamus, and breast lesion, and 16% in muscle. Our recommended protocol, 15-min early dynamic scan plus a 5-min late scan with DL, remained robust to up to a 5-fold dose reduction (~74 MBq). Overall, these findings support DL-enabled abbreviated, low-dose dynamic LAFOV PET as a clinically feasible approach for accurate kinetic quantification

Purpose: Respiratory motion remains a major source of quantitative bias in PET and becomes increasingly relevant for high-sensitivity long axial field-of-view (LAFOV) PET/CT. Although numerous respiratory motion correction (MoCo) methods have been proposed, their quantitative accuracy cannot be established clinically because a patient-specific motion-free reference is fundamentally unavailable in vivo. This study combined clinical PET imaging with a digital twin, a realistic representation of both the PET/CT system and the patient, to objectively validate respiratory MoCo against a corresponding motion-free reference. Methods: Twenty patients (10 [18F]FDG with predominantly pulmonary lesions and 10 [18F]SiFAlin-TATE with predominantly hepatic lesions; total 135 lesions) were analyzed. The digital twin combined a validated LAFOV PET/CT simulation model with an anatomically realistic phantom containing 14 lung and liver lesions, two patient-derived respiratory patterns, and respiratory motion amplitudes of 2 and 3 cm, generating patient-like datasets with corresponding motion-free references. Data-driven and image-based MoCo were evaluated using lesion morphology, SUVmean, SUVmax, and metabolic tumor volume (MTV). Results: In patients, data-driven MoCo produced larger SUVmean increases than image-based MoCo for liver (48.1{+/-}18.9% vs. 17.0 {+/-} 12.0%; p<0.01), lower-lung (32.5{+/-}21.2% vs. 16.3{+/-}15.6%, p=0.06), and upper-lung lesions (28.4{+/-}32.0% vs. 10.4 {+/-} 17.2%; p<0.01), with similar findings for SUVmax and larger MTV reductions. Simulation revealed marked motion-induced SUVmean underestimation before correction, particularly in liver (-31.2{+/-}6.8%) and lower lung (-15.5{+/-}13.9%). Relative to the motion-free reference, data-driven MoCo most accurately recovered hepatic uptake (4.3{+/-}11.7% vs. -10.0 {+/-} 9.2%; p=0.01) but overestimated pulmonary uptake (lower lung: 19.8{+/-}16.3% vs. -1.6 {+/-} 10.2%; p=0.02). SUVmax showed the same regional behavior, whereas image-based MoCo yielded MTV estimates closer to the reference. Quantitative recovery was largely independent of respiratory pattern, while larger motion amplitudes mainly affected image-based MoCo. Conclusion: Combining clinical PET with a realistic digital twin and corresponding motion-free ground truth enabled objective validation of respiratory MoCo beyond conventional clinical evaluation. Larger correction-induced quantitative changes should not be equated with greater quantitative accuracy. Instead, MoCo performance was region- and metric-dependent, highlighting the value of ground-truth-based validation for developing and benchmarking respiratory motion correction and quantitative PET on LAFOV PET/CT systems.

Background. Roughly, half of new type 1 diabetes (T1D) diagnoses occur in individuals under 18 years old and represent a more aggressive destruction of beta cell mass (BCM). [11C]-(+)-PHNO positron emission tomography (PET) imaging is used to assess BCM, but current pancreas PET imaging protocols are limited to adults. Previously published full count data from six healthy controls and five T1Ds (6M/5F; 22 to 53 years old) were used for retrospective analysis. Dynamic [11C]-(+)-PHNO PET/CT scans were acquired and reconstructed using full-count list-mode data. For the current comparison to full count data, 50%, 25% and 10% down-sampled count data were re-reconstructed. Pancreas and spleen (reference region) time-activity-curves (TACs) were assessed, and volume of distribution (VT, mL/cm3) was estimated using the reversible 1-tissue compartment model (1TC) with tmax of 30 min for all count levels. Pancreas and Spleen VT estimates (1TC; tmax= 30 min) were used to calculate non-displaceable binding potential (BPND) and were then correlated to semi-quantitative methods of standardized uptake value ratio (SUVR-1) (20-30 min; ref: spleen) to examine simplified methods using simulated low dose protocols. Finally, we performed dosimetry in adult, adolescent and pediatric phantoms to assess radiation dose for simulated low-dose protocols. Results. Qualitatively, increasing noise can be visualized at successive reduced-count levels images, compared to full-count images. Despite progressively increasing noise in reduced-count images, TACs at each reduced-count level remained similar to full-count TACs in both HC and individuals with T1D. Quantitatively, 1TC VT estimates were similar for all reduced count levels and range of tmax values, compared to full-count (all R2[&ge;]0.99). Pancreas SUVR-1 (20-30 min) and pancreas BPND (tmax = 30; ref: spleen) were highly correlated for all count levels (all R2[&ge;]0.80). All age groups were under both the yearly occupational and research scan radiation dose limits when examining mean effective dose equivalent with reduced (1/10th) injected dose protocols. Conclusion. Low-count reconstructed data and simplified reference region approaches provide accurate quantification compared to full-count reconstructions. These results provide evidence that it is possible to perform accurate quantification using simulated low dose protocols to quantify BCM for use in individuals with T1D under 18 years old.

Introduction: A new method that corrects for time-dependent bias in standardized-uptake value ratios (SUVRs) was adapted and optimized for [11C]PiB (PiB) amyloid-beta (A{beta}) PET, across low-to-high A{beta} loads, relying only on PET data collected during the SUVR time-window. This modeling approach was evaluated in cross-sectional and longitudinal cohorts for earlier and shorter SUVR time-windows (30-45 min, 45-60 min) than commonly applied, to enable higher throughput imaging. Methods: The SUVR correction (SUVRc) approach was optimized and tested on separate cross-sectional (n=88), and longitudinal (36 participants, two time-points, 72 images) cohorts from the Harvard Aging Brain Study. The cross-sectional cohort spanned low, intermediate and high levels of cortical A{beta} pathology and the longitudinal images included two cohorts with low (5-10%) and high levels (~40%) of A{beta} change. SUVR and SUVRc were compared against SRTM DVR (0-60 min) to quantify A{beta} burden through Pearson's and Lin's correlations, difference plots and longitudinal change. Results: The mean regional bias in PiB SUVR (5-15%, depending on time-window and A{beta} burden) was significantly reduced to < 3% by SUVRc (corrected p < 0.05) in the cross-sectional cohorts for all time-windows, along with reductions in bias variability. SUVRc also showed higher Pearson's correlation (r) and Lin's concordance (LCC) with DVR across time-windows (r=0.98, LCC=0.99 at 30-45 min and 45-60 min) compared to uncorrected SUVR (r=0.96, LCC=0.95 at 30-45 min, r=0.97, LCC=0.92 at 45-60 min). Bland-Altman plots confirmed better agreement between SUVRc and DVR (mean bias at 30-45 min: 0.02 for SUVRc, 0.10 for SUVR; mean bias at 45-60 min: 0.01 for SUVRc, 0.17 for SUVR). Longitudinal DVR changes were more accurately represented by SUVRc, compared to uncorrected SUVR. Conclusions: SUVRc for [11C]PiB PET enables more accurate quantification of A{beta} burden than SUVR in cross-sectional and longitudinal studies (relative to SRTM DVR), while enabling imaging at earlier and shorter time-windows. The improved accuracy would be beneficial in better quantifying amyloid re-emergence post anti-amyloid therapy and could be used for kinetic harmonization across time-windows and radiotracers.

Purpose: Attenuation correction (AC) of PET images is essential for accurate quantification. Brain PET studies comprising simultaneous EEG (PETEEG) may suffer from metal artifacts in CT images (CTEEG), or improper correction when electrodes are not present in the CT (CT0). As these influences are not well-characterized, we aim to compare metal artifact reduction (MAR) techniques for CTEEG images, and evaluate differences between attenuated-corrected PETEEG using CT0 and CTEEG with MAR, synthetically placed electrodes (CTEEG-synth) and extended Hounsfield unit (HU) range. Methods: 19 healthy participants underwent two total-body PET/CT scans with [18F]FDG, with and without 32 EEG scalp electrodes, respectively. We evaluated five MARs to reduce streaks caused by the EEG electrodes in the CTEEG. Finally, CT0, CTEEG with (CTEEG-iMAR-Ext) and without extended HU range (CTEEG-iMAR) and CTEEG-synth were used to perform attenuation correction of PETEEG. We compared our results to PET0/CT0 scan using relative differences. Results: CTEEG and CTEEG-iMAR showed the smallest differences to CT0. PETEEG/CTEEG-iMAR-Ext exhibited the lowest differences to PET0/CT0 (average bias across all regions of -0.46%), followed by similar performance of PETEEG/CTEEG-iMAR (-0.73%) and PETEEG/CTEEG (-0.76%). Conversely, PETEEG/CT0 demonstrated the largest average differences (-1.81%), with values reaching -2.71% in the parietal lobe. These differences were consistent across subjects, yielding significant effects in most of the brain (pFWE < 0.05). CTEEG-synth performed not as good as CTEEG (-1.21%). Conclusions: CTEEG with extended HU range is most suitable for attenuation correction of PETEEG images, with MAR correction offering little additional improvement.

Fluorescence imaging in the second near-infrared window (NIR-II, 950-1700 nm) offers reduced scattering, lower autofluorescence, and deeper tissue penetration than NIR-I imaging, but its adoption is limited by the need for custom-synthesized fluorophores. Here, we identify commercially available dyes that exhibit usable NIR-II emission. Eleven visible, far-red, and NIR-I fluorophores were screened under twelve acquisition configurations combining 670, 760, and 808 nm excitation with band-pass (950 nm, 1400 nm) or long-pass (1000 nm, 1250 nm) emission filters. Output varied markedly with fluorophore identity and excitation/emission configuration. Among hydrophobic dyes, DiR exhibited strong emission across almost all excitation and emission filters. Among hydrophilic dyes, strong NIR-II fluorescence was observed for IRDye 680RD (excitation at 670 nm), sulfo-cyanine 7 (excitation at 670 nm and 760 nm), and indocyanine green (excitation at 808 nm). DiR showed a linear concentration-response under 760 nm excitation with BP1400 detection. Upon encapsulation in PEGylated liposomes, strong NIR-II fluorescence was retained. In an in vivo study in mice, NIR-II resolved vasculature that NIR-I could not consistently delineate, and enabled pharmacokinetic analysis. Both windows returned similar ex vivo organ distributions. NIR-II imaging is therefore accessible using commercial off-the-shelf fluorophores, provided the dye is matched to the intended excitation/emission configuration.

Rationale: Neuroblastoma is a devastating pediatric malignancy, for which surgical resection is a key factor in long-term survival. However, there are significant challenges in its resection, particularly in high-risk disease, as neuroblastoma encases surrounding critical structures, is often difficult to distinguish from desmoplastic or scar tissue, and can carry occult deposits of disease not readily identified on preoperative imaging or intraoperative visualization. Building on the principles of fluorescent and radio-guided surgery, in combination with the known overexpression of GD2 in neuroblastoma, we sought to develop and optimize 111In-Dinutuximab-IRDye800, a dual-modality GD2-targeted intraoperative molecular imaging agent, for use in pediatric neuroblastoma to help enhance patient safety while facilitating a more complete resection. Methods: Dinutuximab was conjugated to IRDye800 and DTPA, then radiolabeled with Indium-111 to yield 111In-Dinutuximab-IRDye800. Optimization occurred through ELISA assay to assess binding affinity, fluorescence intensity analysis to determine the optimal fluorescent degree of labeling, and phototoxicity testing through flow cytometry. Rodent models of neuroblastoma were then generated through injection of SK-N-BE(2) human neuroblastoma cells into the left adrenal glands of nude mice or RNU rats. A series of fluorescent and gamma biodistributions was performed, varying the dose, timing, and specific activity of the tracer. Tumor and organ uptake of the tracer was compared with one- or two-way ANOVA as appropriate, with Sidaks multiple comparison test to compare tumor uptake to individual organs. Once optimization was complete, a clinically significant events study modeled after human clinical trials was performed to evaluate the in vivo capabilities of 111In-Dinutuximab-IRDye800. Results: Increased ratios of IRDye800 per antibody led to decreased binding affinity for GD2 and was associated with formulation instability without significant return on fluorescence intensity. Specific activity of the tracer was not found to impact overall biodistribution of the tracer. A 45-50 microgram dose of 111In-Dinutuximab-IRDye800 with ratios around 1 DTPA and 1-1.5 IRDye800 per antibody imaged 4 days after tracer administration was found to be the optimal combination that maximized detectable tumor-specific signal. In the clinically significant events study mirroring human IMI clinical trials, fluorescent guidance identified additional malignant lesions not originally detected under white light in 64% of rodents. Conclusions: 111In-Dinutuximab-IRDye800 is a dual-modality GD2-targeted intraoperative imaging agent that is well-poised for clinical translation. As it preserves tumor specificity, yields clinically meaningful radiofluorescent signal, and is well-tolerated without adverse events after optimization was completed, it carries the potential to positively impact the safety and completeness of neuroblastoma resection.

Background: Trophoblast cell surface antigen 2 (TROP2, encoded by TACSTD2) is a transmembrane glycoprotein overexpressed in multiple aggressive epithelial carcinomas. While antibody drug conjugates targeting TROP2 have achieved regulatory approvals, acquired payload resistance and systemic off-target toxicities limit sustained remissions. Radionuclide Drug Conjugates (RDCs) represent a potent alternative modality capable of delivering cytotoxic ionizing radiation directly to target cells. However, selecting the optimal therapeutic radioisotope between long-range beta emitters (177Lu) and short-range, high linear energy transfer (LET) alpha emitters (225Ac) under heterogeneous TROP2 spatial distributions remains an unaddressed clinical challenge. Methods: We developed an automated computational pathology and spatial microdosimetry pipeline to resolve microscopic TROP2 expression gradients and simulate absorbed radiation dose distributions from digitized whole-tissue immunohistochemistry (IHC) sections (N = 14). Optical density matrices were de-convoluted in Hematoxylin-Eosin-DAB (HED) color space to isolate the DAB chromogen. Continuous 2D spatial density distributions and topological surface profiles were reconstructed. Physical radiation energy deposition was modeled using radial dose point kernels for 177Lu (mean range ~670 m, LET 0.2 keV/m) and 225Ac (mean range ~65 m, LET 100 keV/m, 4 alpha particles per decay cascade). Therapeutic Index (TI, ratio of mean target to non-target absorbed dose), target coverage, and spatial specificity were quantified across all specimens. Results: Quantitative image deconvolution revealed that TROP2 expression across the cohort was characteristically focal and clustered, with a mean positive area fraction of 1.55 +/- 2.22% (range: 0.08% to 6.85%) and mean DAB signal intensity of 0.256 +/- 0.043. In all 14 evaluated specimens (100%), 225Ac-labeled RDCs demonstrated superior tumor-to-stroma dose localization compared to 177Lu-labeled RDCs. The cohort-wide mean Therapeutic Index was significantly higher for 225Ac (1.26 +/- 0.14) than for 177Lu (1.01 +/- 0.02, p < 0.0001, paired two-tailed t-test). Because the path length of 177Lu beta particles exceeded target cell nest dimensions by up to 30-fold, 177Lu suffered from severe off-target crossfire spillover into antigen-negative stroma. In contrast, 225Ac confined high-LET ionization tracks strictly within the micro-geographic boundaries of TROP2-expressing clusters. Conclusions: In tumors displaying focal or sparse TROP2 micro-architecture, Targeted Alpha Therapy with 225Ac-RDCs offers a superior biophysical profile over beta-emitting 177Lu-RDCs, maximizing cluster cell kill while sparing adjacent normal tissue stroma. This computational microdosimetry framework provides a practical tool to guide rational isotope pairing in RDC drug design.

Introduction: Anesthesia is known to modulate glymphatic clearance and cerebrospinal fluid (CSF) transport in rodents, but how these effects translate to a larger, gyrencephalic brain is unknown. With its anatomical similarity to the human brain, the pig offers a valuable translational model for examining anesthesia-dependent CSF-to-brain transport. Methods: We used dynamic in vivo SPECT/CT imaging for six hours following cisterna magna injection of [99mTc]-DTPA to quantify CSF-to-brain tracer transport in pigs under two anesthesia regimens: ketamine/dexmedetomidine (K/D, n=5) which previously has been shown in rodents to enhance glymphatic influx relative to GABAergic anesthesia, and propofol (PRO, n=5). Brain and CSF spaces were delineated using a data-driven non-negative matrix factorization approach, and tracer kinetics were quantified using a one-tissue compartment model. Results: Brain influx could be stably estimated from 2 hours post-injection. Hierarchical sub-division of the brain parenchyma identified two kinetically distinct components with different anatomical distributions: a surface component, located ventrally and within the interhemispheric fissure, showed faster kinetics than the anatomically deeper and lateral-dorsal component. Consistent with rodent findings, K/D-anesthetized pigs showed 62% (p=0.002) greater brain tracer accumulation than PRO-anesthetized pigs. However, while the brain influx rates did not differ substantially (p=0.047), a 52% higher cumulative CSF tracer concentration (p=0.047) could account for most of the difference by providing greater tracer availability for brain entry. Conclusions: In the larger gyrencephalic pig brain, we found higher brain tracer accumulation under K/D anesthesia compared to PRO anesthesia. A significant portion of this difference is readily explained by higher CSF retention, likely driven by a slower CSF turnover. This underscores the necessity of dynamic CSF tracer concentration measurements when assessing CSF-brain influx, a factor we suggest that future glymphatic studies should take into account.

BACKGROUND: Quantitative amyloid-beta (A{beta})-PET is increasingly used in AD prevention trials. Although the Centiloid (CL) framework provides a common scale, variability persists across processing pipelines, including differences in template/native space, partial volume correction (PVC), and reference region. These choices may influence cut-points, and in turn positivity rates, as well as longitudinal accumulation rates. We examined cut-point estimates and inter-pipeline discordance in a community cohort where many are expected to have early A{beta} deposition. METHODS: We analysed [18F]florbetapir PET/MR data from predominantly cognitively unimpaired (~95%) individuals aged ~71 years at baseline (n=433) and at follow-up (n=328; ~2.4-year interval) in Insight 46 (1946 British birth cohort). Centiloids were derived using the standard pipeline and ten in-house pipelines employing alternative reference regions and PVC in native space. Gaussian mixture modelling estimated cut-points with bootstrapped uncertainty. We assessed A{beta}-discordance across pipelines as a function of standard CLs and examined follow-up CSF A{beta}42/A{beta}40 (n=120) and PET in individuals with discordant baseline classifications. RESULTS: Baseline cut-points were 10-23 CL across pipelines, classifying 16-25% as A{beta}-positive. Reliable accumulation cut-points were 3.5-6 CL/year, identifying 16-22% as accumulators. Uncertainty varied across pipelines. At baseline, 18% were discordant across PET measures, predominantly between 11-35 standard CLs. The discordant group showed higher A{beta}-PET accumulation and lower CSF A{beta}42/A{beta}40 than concordant negatives. CONCLUSIONS: Disagreement between A{beta}-PET methods was highest between 11-35 standard Centiloids and was frequently associated with accumulating A{beta}. These findings highlight the importance of considering cut-point uncertainty and methodological influences when interpreting early-stage amyloidosis.

Background: Positron emission tomography (PET) myocardial perfusion imaging (MPI) provides complementary information on perfusion, myocardial blood flow and ventricular function. While these markers are often considered collectively during interpretation, their quantitative integration with imaging and clinical data into a unified predictive framework remains limited. We developed a multimodal artificial intelligence framework that combines PET polar maps with quantitative imaging and clinical features to improve obstructive coronary artery disease (CAD) detection. Methods: We retrospectively analyzed the multicenter REFINE PET registry. Among 38,682 PET MPI studies from 14 sites, 2,833 patients without known prior CAD underwent invasive coronary angiography within 180 days. Obstructive CAD was defined as >=50% left main stenosis or >=70% stenosis in other major epicardial coronary arteries. We developed a two-stage contrastive learning framework to learn multimodal PET representations from studies without angiographic labels and transfer them to supervised CAD prediction. In Stage 1, PET image and tabular encoders were pretrained on 12,225 PET MPI studies from eight development sites using 15-channel PET polar maps, quantitative PET perfusion, flow and gated functional measures, and clinical variables. In Stage 2, the pretrained encoders and a lightweight classification head were fine-tuned in 968 angiography-labeled patients, using lower encoder learning rates to limit overfitting. The model was externally validated for angiographically defined obstructive CAD detection in 1,865 patients from six independent sites and compared with standard PET MPI metrics. Results: The prevalence of obstructive CAD was 60% in the training cohort (66% male, median age of 70 years [63, 77]), and 55% in the external validation cohort (64% male, median age of 67 years [60-74]). In external validation, the AI model achieved an AUC of 0.85 (95% confidence interval (CI), 0.83-0.87) for obstructive CAD detection and outperformed conventional quantitative PET metrics (all P < 0.001). At a specificity matched to visual summed stress score, the AI model achieved higher sensitivity (89% [95% CI, 87-91] versus 85% [95% CI, 82-87]) and negative predictive value (81% [95% CI, 77-84] versus 73% [95% CI, 69-77]; both p<0.001). The overall net reclassification improvement was 8.9% (95% CI, 4.2-13.6%; p = 0.001). Conclusions: Multimodal contrastive pretraining improved obstructive CAD detection from PET imaging beyond conventional perfusion-based scoring in independent multisite external validation.

Background: Plasma phosphorylated tau at threonine 217 (p-Tau217) is a leading blood-based biomarker for Alzheimer's disease (AD). Robust analytical characterization on high-throughput platforms is essential for research use and clinical translation. Objective: To evaluate the analytical performance of an automated plasma p-Tau217 immunoassay and characterize its discrimination of PET-defined amyloid status. Methods: We performed analytical validation of the Access Research Use Only (RUO) plasma p-Tau217 immunoassay on the Beckman Coulter DxI 9000 Access Immunoassay Analyzer and evaluated biomarker discrimination of PET-defined amyloid pathology in a subset of the Bio-Hermes-001 cohort spanning the symptomatic cognitive continuum (mild cognitive impairment or mild AD dementia; cognitively unimpaired participants excluded; n = 449). Analytical precision, sensitivity, linearity, specificity, interference, and sample stability were assessed per Clinical and Laboratory Standards Institute guidelines. Discrimination of PET-defined amyloid status was evaluated using receiver operating characteristic curve and indeterminate zone analyses. Results: The assay demonstrated high precision (within-laboratory CV </=7.1%), excellent sensitivity (limit of detection 0.018-0.021 pg/mL), linearity across the analytical measuring range (R-squared > 0.99), strong epitope specificity (</=1.0% cross-reactivity with other tau phosphoisoforms), and minimal interference from over 60 endogenous and exogenous substances. In 449 research participants plasma p-Tau217 showed strong discrimination between amyloid-positive and amyloid-negative groups (AUC 0.881; 95% CI 0.846-0.915). Application of indeterminate zones systematically improved classification metrics at the cost of fewer definitive classifications. Conclusions: These findings support the Access p-Tau217 (RUO) assay as a robust, high-throughput assay for plasma biomarker-based discrimination of PET-defined amyloid pathology in AD applications.

Spectral computed tomography (CT) is a burgeoning quantitative imaging technique with applications in oncologic diagnostics, prognostic prediction, tissue perfusion studies, and treatment follow-up. While normalized iodine concentration values have been correlated with microenvironmental biophysical changes, obtaining accurate iodine concentrations, particularly at low concentrations remains difficult due to varying spectral CT instrumentation performance. Hybrid spectral CT systems, combining multiple spectral CT instrumentation techniques, address these quantitation insufficiencies by increasing spectral separation but have not been evaluated on a clinically analogous platform. We validate a hybrid spectral CT system, comprised of clinical-grade components, acquiring four distinct effective spectra and applying efficient noise-reducing weighting schemes to compare iodine noise and bias against conventional kVp-Switching (kVp-S). Two tube current levels (50, 350 mA) and three duty cycle ratios (33/67, 50/50, 75/25) were implemented to elucidate radiation dose exposure and kVp-S parameterization impact. A standard quality assurance (QA) and patient-derived, abdominal IodinePrint phantom were scanned on the system. The average absolute bias in iodine density images of the QA phantom was comparable across acquisition techniques, below 0.5 mg/mL, while quantitative noise improved by 22% using noise-optimized weighting schemes. In the IodinePrint phantom aorta and pancreas structures, the noise-optimized weighting scheme increased signal-to-noise ratio (SNR) by 1.3x compared to kVp-S alone. These results highlight the increased precision of hybrid, multi-channel spectral CT systems and motivate CT designs that enable robust CT biomarker development.

Targeted radiopharmaceutical development for ovarian cancer (OC) has been limited by the lack of molecular targets that combine broad tumor expression with minimal normal-tissue distribution. TRA-1-60 (TRA) is a cancer-associated glycoepitope carried by podocalyxin. Here, we evaluated TRA as a target for OC and developed a TRA-directed immunoPET imaging platform. Immunohistochemical analysis demonstrated significantly higher TRA expression in ovarian tumors than in normal adjacent ovarian tissue, with expression maintained across epithelial OC histotypes and disease stages. An engineered anti-TRA single-chain variable fragment-Fc (scFv-Fc) demonstrated robust penetration of three-dimensional tumor spheroids and selective accumulation in intraperitoneal tumors in an immunocompetent syngeneic OC model. Radiolabeling with zirconium-89 generated [Zr]Zr-DFO-anti-TRA scFv-Fc with >98% radiochemical yield. Serial PET/CT imaging demonstrated progressive and sustained radiotracer accumulation at tumor sites through 96 hours, accompanied by declining liver-associated activity and low uptake in most normal tissues. Together, these findings identify TRA as a broadly expressed and accessible tumor-associated glycoepitope and establish TRA-targeted immunoPET as a promising strategy for noninvasive detection of OC. The selective and sustained tumor localization of this platform further provides a foundation for development of TRA-directed radiopharmaceutical therapy, supporting a potential theranostic approach for OC.

Automated lesion segmentation is increasingly central to PSMA PET/CT interpretation, supporting staging, treatment planning, and response assessment at a scale that outpaces available nuclear-medicine expertise. However, automated PSMA-PET/CT whole-body lesion segmentation models are trained on images alone, with no knowledge of where in the body prostate metastases actually tend to occur. Radiologists use clinical domain knowledge of metastatic spread, but its absence in machine learning models produces false positives in anatomically implausible locations and missed lesions in high-risk sites such as the liver. In this work, we explore whether population-level spatial knowledge of metastatic spread can be used to augment deep learning segmentation predictions, and how such a prior should be fused with a network's output, without additional training. We build a data-driven metastasis atlas from 375 expert-annotated whole-body PSMA PET/CT scans and investigate its fusion with a trained segmentation network under a Bayesian framework, in which prediction probabilities from an nnU-Net-based lesion segmentation model serve as the likelihood and the data-driven atlas as the prior. Because metastases occupy only a small fraction of whole-body voxels, the atlas's peak probability is too low, and standard power-scaled or naive Bayesian pooling references lack the tools to deal with this shortcoming. This causes these standard fusion strategies to fail and, in the naive Bayesian case, to sharply degrade performance. We instead derive a calibrated, background-referenced log-odds fusion, one of many possible approaches to combine a population atlas with a deep learning model's predictions, distinct from classical multi-atlas label fusion in that it fuses a single population prior with a trained network's softmax rather than combining several registered atlases. Furthermore, this approach is neutral outside atlas support by construction, reduces exactly to the baseline network when unweighted, and requires no retraining. This atlas fusion significantly improved mean Dice over the baseline nnU-Net on a disjoint internal test set ($+0.011$, Holm-adjusted $p=0.021$) and on an independent external cohort ($+0.0129$, Holm-adjusted $p=3.8\times10^{-16}$), with lesion sensitivity improving from 0.849 to 0.861 internally and Dice improving over baseline in every stratified anatomic region, including the rare, high-risk sites motivating this work, while naive Bayesian pooling degrades performance sharply and power-scaled pooling underperforms it throughout. Our findings suggest that population-level spatial priors can meaningfully augment deep learning predictions in whole-body oncologic segmentation, provided the fusion rule is calibrated to where the prior actually carries signal.

Missing or degraded sequences can limit prostate multiparametric MRI. We developed MSCNet, a sequence-conditioned cross-modal generative framework for reconstructing unavailable contrasts and restoring degraded acquisitions. Across ten completion tasks, task-specific MSCNet achieved mean structural similarity of 0.818 versus 0.798 for the strongest task-matched comparators; matched-capacity analyses showed larger differences in lesion fidelity and boundary preservation. In a blinded 1,000-case reader study, overall image quality met the prespecified non-inferiority criterion for DWI, ADC and T2W completion, but not T1W. In a separate 200-case diagnostic assessment, AUCs for clinically significant cancer were 0.860 with acquired images, 0.841 with MSCNet and 0.797 with baseline-generated images. A locked 186-case three-hospital cohort supported multicentre transportability. These retrospective results support quality-controlled cross-modal reconstruction as an adjunct to acquired prostate MRI.

Studies in humans and murine models have pointed towards a possible link between metabolic syndrome, which shows insulin resistance and metabolic dysregulation, and Alzheimer's disease (AD) pathology marked by amyloid-beta (A{beta}) accumulation and hypometabolism in the brain. Yet, the underlying biological mechanisms by which metabolic syndrome affects these pathological changes in AD brain remain unknown. We hypothesized that insulin resistance is responsible for alterations in blood-brain barrier (BBB) transport of A{beta} peptides and glucose. This hypothesis was tested by employing radiolabeled ligands (125I-A{beta}40, 125I-A{beta}42, and 18F-FDG) in high-fat diet (HFD)-fed mouse models that manifest metabolic syndrome. Further, we assessed alterations in the expression of various molecular mediators within the brain microcapillaries harvested from both low-fat diet (LFD)-fed and HFD-fed mice. Our findings show that HFD-fed mice developed peripheral insulin resistance and obesity. In addition, HFD-fed mice demonstrated an increase in the influx rate of A{beta} peptides and a reduction in 18F-FDG (a glucose surrogate) influx rate compared to LFD-fed mice. These transport changes are associated with the increase in the BBB endothelial expression of RAGE (receptor to traffic A{beta} from plasma-to-brain) and reduction of GLUT1 (glucose transporter) expression in HFD-fed mice compared to LFD-fed mice. Moreover, disruption in insulin signaling, as indicated by reduced pAKT and pERK expression, was observed in HFD-fed mice. Inhibiting AKT or ERK phosphorylation resulted in similar changes in A{beta} and glucose uptake in polarized BBB endothelial cell monolayers in vitro. These results indicate that high-fat diet induced metabolic syndrome may lead to BBB dysfunction, characterized by increased plasma-to-brain A{beta} trafficking and diminished glucose transport at the BBB, thereby aggravating the expression of AD pathological hallmarks.

Background: The Centiloid (CL) scale standardizes global amyloid PET quantification and is widely used to define amyloid positivity. As a global summary measure, however, CL may not fully reflect the regional distribution of amyloid deposition, which can carry additional prognostic information about the rate of cognitive decline. Objective: To develop and externally validate a fixed, regional amyloid PET composite score that complements CL for predicting cognitive decline in Alzheimer's disease. Methods: The Regional Amyloid PET Score (RAPS) was derived from 82 FreeSurfer regions using machine learning with bootstrap stability selection to predict the rate of change in CDR-Sum of Boxes (CDR-SB) in 433 amyloid-positive ADNI [18F]florbetapir participants. The fixed nine-region weights were applied without retraining in a cross-tracer ADNI [18F]florbetaben subset (N = 71; largely overlapping the discovery participants) and two external validation cohorts, NACC SCAN (N = 1531; four tracers) and OASIS-3 (N = 428). Results: RAPS comprised nine regions. In ADNI, RAPS correlated more strongly with CDR-SB slope than CL and showed higher discrimination of rapid decliners (AUC 0.813 vs 0.713). Performance was directionally consistent across validation cohorts; in NACC SCAN, RAPS and CL independently predicted clinical progression. Cross-cohort meta-analysis of the three independent cohorts supported incremental discrimination beyond CL (pooled {Delta}AUC +0.066; I2 = 0%). Conclusions: RAPS, a fixed regional amyloid PET-derived score, may complement CL for prognostic stratification in Alzheimer's disease research.

BackgroundSingle-voxel magnetic resonance spectroscopy (MRS) is a non-invasive method for measuring clinically and cognitively relevant metabolites. Reliable measurements require precise voxel placement across sessions and participants. We developed a scanner-console-based approach to improve voxel placement precision. MethodsIn a crossover design (n=7; six sessions each), we compared test-retest reliability of three voxel placement methods in a reference benchmark (left parietal cortex) and a technically challenging region (left ventromedial prefrontal cortex). Methods included (1) conventional anatomy-based placement, (2) mask-guided real-time positioning (MGRP), and (3) semiautomated session-locked voxel repositioning (SSVR). Resting-state MRS data were acquired using PRESS and MEGA-PRESS. Within-subject reliability of voxel placement and metabolite concentrations, namely, total N-acetylaspartate (tNAA), total Creatine (tCr), GABA (gamma-aminobutyric acid), and Glx (glutamate + glutamine) are reported using the coefficient of variation (CV), the intraclass correlation coefficient (ICC), minimal detectable change (MDC), and the spatial overlap. ResultsSSVR markedly improved voxel placement reliability, increasing spatial overlap (up to 88%) and achieving near-perfect geometric reproducibility (ICC = 0.99) compared to conventional anatomy-based placement and MGRP. SSVR improved tissue composition consistency and reduced metabolite variability in the technically challenging region (variability reduction of [~]70% tCr, [~]59% tNAA, and [~]51% Glx) while further refining already stable measurements in the benchmark region (tNAA from [~]15% to [~]10%). ConclusionBoth MGRP and SSVR improved voxel placement and metabolite measurement reproducibility compared with conventional anatomy-based placement. SSVR further enhanced within-subject reproducibility across repeated sessions, particularly in the technically challenging region, providing a robust approach for longitudinal single-voxel MRS studies.

The limited efficacy of immune checkpoint inhibitor (ICI) therapy in triple-negative breast cancer (TNBC) highlights the need for combination strategies that enhance antitumor responses. Sorafenib, a multikinase inhibitor with anti-angiogenic and immunomodulatory activity, represents a rational partner for ICI-based combination therapy. However, therapeutic responses to such combinations are biologically complex and cannot be fully characterized by any single biomarker or imaging modality. Here, we evaluated ICI therapy combined with sorafenib in the aggressive and ICI-refractory orthotopic 4T1 TNBC model. Therapeutic responses were assessed using a unique longitudinal multimodal imaging framework integrating [Zr]Zr-DFO-anti-CD8 minibody and [{superscript 1}F]FDG PET, as well as perfluorocarbon (PFC)-based {superscript 1}F MRI and hyperpolarized {superscript 1}3C MRS, together with ex vivo analyses. Only the ICI-sorafenib combination suppressed tumor growth, whereas both monotherapies showed limited antitumor activity. Multimodal imaging, together with complementary ex vivo analyses, uncovered coordinated tumor microenvironment (TME) remodeling, including vascular normalization, elevated CD8 cell presence with modest enrichment in the tumor center, delayed increase in phagocyte-associated {superscript 1}F MRI signal coupled with reduced CD206 cell infiltration, and sustained metabolic activity. These findings support ICI-sorafenib combination therapy as a promising therapeutic strategy for TNBC. Therapeutic efficacy reflected coordinated vascular, immune, and metabolic remodeling. This multimodal imaging framework enables non-invasive longitudinal monitoring of these complementary TME changes, providing a comprehensive strategy for treatment assessment in immunotherapy-based combination therapies. One Sentence SummaryLongitudinal multimodal imaging identified a multidimensional TME response signature of effective ICI-sorafenib therapy in TNBC.